-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
SARS-CoV-2-nsp13-IN-4
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/923140-39-0.gif)
| Category | SARS-CoV |
| CAS | 923140-39-0 |
| Description | SARS-CoV-2 nsp13-IN-4 (C4 (d)) is a potent and selective nsp13 helicase small-molecule inhibitor and inhibit the ssDNA+ ATPase activity of nsp13 with an IC50 value of 57 μM. SARS-CoV-2 nsp13-IN-4 is druglike molecule with molecular weight of less than 450Da and can provide a broad-spectrum antiviral effect. |
Product Information
| Synonyms | SARS-CoV-2 nsp13-IN-4|3-bromo-N-(4-(7-methylimidazo[1,2-a]pyrimidin-2-yl)phenyl)benzamide|3-bromo-N-[4-(7-methylimidazo[1,2-a]pyrimidin-2-yl)phenyl]benzamide|ZINC9572073|HY-150625|CS-0534897|F2206-0115 |
| Molecular Weight | 407.26 |
| Molecular Formula | C20H15BrN4O |
| Canonical SMILES | CC1=NC2=NC(=CN2C=C1)C3=CC=C(C=C3)NC(=O)C4=CC(=CC=C4)Br |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 496 |
| Exact Mass | 406.04292 |
| In Vitro | SARS-CoV-2 nsp13-IN-4 (C4 (d)) inhibits the ssDNA+ ATPase activity and the ssDNA- ATPase activity of nsp13 with IC50 values of 57 μM and 240 μM, respectively. |
| Target | IC50: 57 μM (nsp13 ssDNA+ ATPase) |
| XLogP3-AA | 4.7 |
